Ignite Creation Date:
2025-12-25 @ 2:37 AM
Ignite Modification Date:
2025-12-26 @ 1:15 AM
Study NCT ID:
NCT06101134
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-14
First Post:
2023-10-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11-06
Start Date Type:
ACTUAL
Primary Completion Date:
2025-04-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-08-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-20
First Submit QC Date:
None
Study First Post Date:
2023-10-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-11
Last Update Post Date:
2025-04-14
Last Update Post Date Type:
ACTUAL